Skin Diseases, Infectious

14
Pipeline Programs
8
Companies
7
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
7
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 7 programs with unclassified modality

On Market (4)

Approved therapies currently available

J&
LEVAQUINApproved
levofloxacin
Johnson & Johnson
oral2004
J&
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINERApproved
levofloxacin
Johnson & Johnson
injection1996
U
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINERApproved
levofloxacin
Unknown Company
injection2024
U
SIVEXTROApproved
tedizolid phosphate
Unknown Company
oral2014

Competitive Landscape

8 companies ranked by most advanced pipeline stage

J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
1
levofloxacinPhase 2/3Small Molecule1 trial
Active Trials
NCT00257036Completed431Est. Feb 1993
Providence Therapeutics
1 program
1
CeftarolinePhase 41 trial
Active Trials
NCT02582203CompletedEst. May 2016
OD
2 programs
1
1
LevofloxacinPhase 3Small Molecule
levofloxacinPhase 2/3Small Molecule
BP
Basilea PharmaceuticaSwitzerland - Allschwil
2 programs
2
Ceftobiprole medocarilPhase 31 trial
ceftobiprole medocarilPhase 31 trial
Active Trials
NCT00228982CompletedEst. Dec 2005
NCT00210899CompletedEst. Oct 2006
Paratek Pharmaceuticals
1 program
1
PTK 0796Phase 3
Novartis
NovartisBASEL, Switzerland
1 program
1
PTK 0796Phase 31 trial
Active Trials
NCT00865280Terminated143Est. Apr 2010
M&
Merck & Co.RAHWAY, NJ
1 program
1
Tedizolid PhophatePhase 31 trial
Active Trials
NCT02276482CompletedEst. Sep 2018
Bayer
BayerLEVERKUSEN, Germany
1 program
1
Tedizolid PhosphatePhase 31 trial
Active Trials
NCT01967225Completed125Est. Oct 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Providence TherapeuticsCeftaroline
Merck & Co.Tedizolid Phophate
BayerTedizolid Phosphate
NovartisPTK 0796
Basilea Pharmaceuticaceftobiprole medocaril
Basilea PharmaceuticaCeftobiprole medocaril
Johnson & Johnsonlevofloxacin

Clinical Trials (7)

Total enrollment: 699 patients across 7 trials

NCT02582203Providence TherapeuticsCeftaroline

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

Start: Feb 2012Est. completion: May 2016
Phase 4Completed
NCT02276482Merck & Co.Tedizolid Phophate

Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)

Start: Mar 2015Est. completion: Sep 2018
Phase 3Completed
NCT01967225BayerTedizolid Phosphate

Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

Start: Nov 2013Est. completion: Oct 2016125 patients
Phase 3Completed
NCT00865280NovartisPTK 0796

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Start: Apr 2009Est. completion: Apr 2010143 patients
Phase 3Terminated
NCT00210899Basilea Pharmaceuticaceftobiprole medocaril

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Start: Sep 2005Est. completion: Oct 2006
Phase 3Completed
NCT00228982Basilea PharmaceuticaCeftobiprole medocaril

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Start: Oct 2004Est. completion: Dec 2005
Phase 3Completed
NCT00257036Johnson & Johnsonlevofloxacin

A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin

Start: Jul 1991Est. completion: Feb 1993431 patients
Phase 2/3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs — potential near-term approvals
8 companies competing in this space